“Magic mushrooms” produce a naturally occurring psychedelic compound called psilocybin. Public opinion surrounding psilocybin mushrooms generally holds that they are primarily used for recreational purposes, which may have contributed to their widespread prohibition in the United States. However, prior studies have demonstrated the potential efficacy of psil...
The etiology of OCD is complex and appears to involve multiple biological pathways. Imbalances in central serotonin, dopamine, and glutamate activities are widely thought to play a causative role. Despite strong evidence supporting first-line OCD pharmacotherapies, approximately 40-60 % of OCD patients remain unresponsive and are considered treatment resista...
Serotonergic psychedelics like psilocybin and LSD have shown potential therapeutic benefits for mental health conditions, including depression, PTSD, and addiction. However, research remains limited due to regulatory barriers and a lack of diversity in study populations. Spanish-speaking individuals, despite their significant global and U.S. presence, are un...
Background and Aims The ongoing opioid epidemic remains a major public health crisis in the United States, with over 100,000 opioid-related deaths annually. Mental health disorders are strongly associated with opioid use disorder (OUD), compounding risks of misuse and overdose. Emerging evidence indicates that psychedelics may be associated with reduced risk...
Investigators will recruit 36 individuals on MAT for OUD for a double-blind, placebo-controlled design to determine whether PEX010 (25-mg/d) shows preliminary efficacy on neural correlates of neurocognition and on clinical outcomes. Participants will be randomized to either (single dose) 25-mg (PEX010-25 group) or 1-mg (PPEX010-1 group) PEX010 in a 2:1 ratio...
Primary Aim: In participants with OUD, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone formulation. Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of a buprenorphine-naloxone maintenance therapy. Secondary Aim: To evaluate the effect of concurrent buprenorphine-...
This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose). Participants will be asked to complete assessments of pain, depre...
Repeated self-administration of small doses of psychedelics, known as microdosing, has been associated with perceived improvements in psychological functioning. However, few studies have examined effects at the daily level. Drawing on data from a naturalistic, prospective, international survey of adults who microdose (N = 1435), we assessed self-reported wit...
Despite psilocybin still being a Schedule I substance in the Federal Controlled Substance Act (OHA, 2022), Oregon voters passed Measure 109 in 2020, now codified into law as ORS457A, which allowed for the opening of psilocybin clinics for eligible clients. The passing of Measure 109 allowed for an adult-use model to be created, which is different from a ther...
BACKGROUND: Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress Reduction (MBSR) and psilocybin have been reported to reduce depressive symptoms, but the efficacy of the combination requires comparison to an active treatment control. We sought to evaluate the safety and prelim...
Rationale: Recent evidence shows that Lysergic Acid Diethylamide (LSD), even when administered in low, non-hallucinogenic doses, can produce analgesic effects and improve pain tolerance in a sample of healthy volunteers. Such results complement what was already observed with other serotonergic psychedelics such as psilocybin: survey studies and case series i...
Psilocybin-containing mushrooms have long been used for their psychoactive effects, but emerging evidence suggests that certain lignicolous (“wood-loving”) species may also induce a distinct toxidrome known as “wood-lover paralysis” (WLP). WLP is characterised by transient weakness following mushroom ingestion, but its aetiology and prevalence remain poorly ...
Abstract Background Psychedelic-assisted therapy (PAT) is gaining attention as a potential treatment for cancer-related psychosocial symptoms. While growing evidence highlights its promise, little is known about how different stakeholder groups perceive its use in oncology and palliative care. Objectives This study aimed to assess stakeholder-specific perspe...
IntroductionPsilocybin shows encouraging outcomes for patients with cancer and major depressive disorder (MDD). However, there is insufficient evidence on the use of evidence-based psychotherapeutic interventions to consistently guide and standardize psilocybin preparation, dosing, and integration. Meaning-centered psychotherapy (MCP) is a manualized, brief ...
The Psilocybe genus is known for producing tryptamine alkaloids, specifically the compounds psilocybin and psilocin, which have shown antidepressant and anxiolytic potential. The presence of these alkaloids makes Psilocybe mushrooms promising sources of molecules with potential applications in the treatment of mental disorders. To explore this, a bibliograph...
Psychedelic research has traditionally focused on controlled, clinical settings to evaluate the therapeutic potential of substances such as psilocybin. However, in recent years, there has been growing interest in naturalistic research, which explores psychedelic use in real-world settings. This review aims to critically analyze trends in naturalistic psyched...
Psilocybin-containing mushrooms have long been used for their psychoactive effects, but emerging evidence suggests that certain lignicolous ("wood-loving") species may also induce a distinct toxidrome known as "wood-lover paralysis" (WLP). WLP is characterised by transient weakness following mushroom ingestion, but its aetiology and prevalence remain poorly ...
Due to psilocybin-assisted therapy's success in previous research, growing cultural awareness and use of psilocybin and other psychedelics, the Oregon Psilocybin Services Act passed by ballot measure in 2020 and began offering services in 2023. While the program has had many successes, a significant problem it faces is affordability and no research to date h...
The goal of this clinical trial is to test the feasibility of combining meditation with psilocybin microdosing in healthy adults. The main questions it aims to answer are: 1. Recruitment and retention feasibility 2. Acceptability, Safety and Tolerability 3. Exploratory Measures: 3.1: Explore potential changes in sleep quality and duration, heart rate variabi...
This study examined patient perspectives on psilocybin therapy, specifically their acceptance and views on the therapeutic benefits of both hallucinogenic and non-hallucinogenic forms. A cross-sectional survey was conducted among psychiatric patients aged 18-65 at a community mental health center, assessing their attitudes, knowledge, and acceptance of psilo...
